Invest in the Future of Neuro-Rescue
SunRegen is developing the first oral neuroprotective therapy for neuronal disorders: a validated mechanism, an unserved market, and a team with the track record to deliver.
SunRegen Healthcare AG is a clinical-stage Swiss biopharmaceutical company advancing SBC003 (the only oral compound with evidence of both protecting neurons against all five major neurotoxic proteins and rescuing neurons already committed to cell death) toward Phase I/II clinical trials in Retinitis Pigmentosa, with a clear platform expansion path into the global neuronal disease market. We are currently building our Series A syndicate of institutional life science investors.
By the Numbers
Investment Highlights
Key metrics that define SunRegen's opportunity as a Series A investment.
Total addressable market
Significant
Neurodegenerative therapeutics is a high-growth category (5.7–7.2% CAGR by 2034). Retinal indications are the de-risked entry point to a much larger CNS opportunity.
Unmet patient need
99%
Of RP patients have no approved disease-modifying treatment. All optic atrophy patients lack neuroprotective options.
Capital invested in SBC003
~$6.3M
Deployed across preclinical development, CMC and GLP toxicology studies, and international research collaborations.
Patents granted
11 countries & regions
WO2017211274A1 granted across 11 countries and regions, including the United States, Canada, Japan, and China, with further applications pending.
Pharma team experience
100+ years
Combined pharmaceutical R&D experience across the scientific team, including 12+ years at Novartis for the CSO.
Series A target
$35M+
To fund IND submission and Phase I/II clinical trials in Retinitis Pigmentosa.
Rescue, not just protection
Functional recovery
Unlike therapies that only slow decline, SBC003 has shown it can act on neurons already committed to cell death, reversing measurable damage in a non-human primate model of optic atrophy. This positions SBC003 as the only investigational oral RP therapy with functional recovery, not just slowed progression.
Why SunRegen
Competitive Advantages
Six structural advantages that compound, from de-risked discovery through granted IP, into a defensible Series A position.
Advantage 01
Phenotype-First, De-Risked Discovery
SunRegen observed SBC003's in vivo efficacy first, then reverse-engineered the exact genetic mechanism. This approach (phenotype validated before target selection) substantially reduces the risk of late-stage clinical failure inherent in conventional target-based drug development.
Advantage 02
20+ Models or 5+ Species Validated Efficacy
Highly converging data across four animal models (NMU, rd10, tMCAO, non-human primates), corroborated by in vitro studies in mouse primary neurons and human iPSC-derived neurons, demonstrates SBC003's consistent efficacy. Multi-species convergence is the strongest preclinical predictor of human clinical success.
Advantage 03
Superior Oral Bioavailability
Unlike gene therapies requiring high-risk subretinal injections, or wet AMD biologics requiring monthly intravitreal injections, SBC003 is administered orally. Fast absorption, favorable brain and retinal exposure, and a low molecular weight profile offer a fundamentally superior patient experience and compliance advantage.
Advantage 04
Mutation-Agnostic Mechanism
By targeting the universal downstream apoptotic pathway rather than an upstream genetic mutation, SBC003 is effective across all genetic subtypes of Retinitis Pigmentosa, potentially addressing 100% of the RP patient population rather than the 0.3–1% eligible for current gene therapies such as Luxturna.
Advantage 05
Granted International IP Protection
SunRegen holds granted patents for the SBC003 compound and its therapeutic applications across major global markets including the United States, Canada, Japan, and China, with ongoing international applications securing long-term commercial exclusivity.
Advantage 06
Pedigreed Scientific Leadership
The scientific advisory board, comprising former leaders from Novartis, Allergan, Alcon, and Harvard Medical School, has collectively managed over 40 successful new drug registrations. This track record directly de-risks the preclinical and clinical development pathway for SBC003.
Investor Relations
We welcome rigorous inquiry from institutional investors and strategic partners interested in SunRegen's Series A financing round.
SBC003 is investigational and has not been approved by any regulatory authority. This page contains forward-looking statements. Actual results may differ materially. Nothing here constitutes an offer to sell or solicitation to buy securities.